Financial Comparison Highlights Royalty Pharma's Institutional Strength and Lower…
1 report, 1 independent
Updated Oct 18
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of Royalty Pharma and Aditxt highlighted differences in financial metrics, including institutional ownership, risk, and analyst ratings. Royalty Pharma has 54.3% of its shares held by institutional investors and a beta of 0.42, indicating lower volatility compared to Aditxt's beta of 1.34. Analysts have given Royalty Pharma a stronger consensus rating and a higher potential upside.
From themarketsdaily.com
Why it matters
The comparison suggests that institutional investors favor Royalty Pharma, which has significantly higher institutional ownership than Aditxt. Royalty Pharma also generates revenue through ongoing royalty rights to products made by AbbVie.
From themarketsdaily.com
Who's involved
- Royalty PharmaBiopharmaceutical company whose stock is being compared and holds royalty rights to AbbVie's products
- Morgan StanleyInvestment bank that actively covers and rates Royalty Pharma
- AbbViePharmaceutical company whose products generate royalty revenue for Royalty Pharma
- Pablo LegorretaFounder and CEO of Royalty Pharma
- Securities and Exchange CommissionGovernment agency that Royalty Pharma must comply with formal regulatory filing requirements set by
Keep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City